Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HEXA | P06865 | 1/20 | 0.42 |
| ▸ | HEXB | P07686 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907080 | 0.98 | FAAH (0.44) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL6565273 | 0.98 | FAAH (0.44) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL4428365 | 0.93 | MEN1 (0.44) | FAAHMGLLMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL12501659 | 0.91 | MEN1 (0.42) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL31065451 | 0.89 | MEN1 (0.52) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL8829446 | 0.87 | FAAH (0.53) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL8626070 | 0.85 | MGLL (0.52) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL8629340 | 0.85 | MGLL (0.52) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL8829438 | 0.85 | MGLL (0.52) | FAAHMGLLMEN1KMT2APOLB | |
| SCHEMBL1982535 | 0.85 | MGLL (0.52) | FAAHMGLLMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-03-10 | — | — | US | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
| CN-113825515-A | Intracellular delivery of anti-KRAS antibodies formulated as nanocapsules | 圣地亚哥德孔波斯特拉大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2021-07-29 | — | — | US | disclosed |
| WO-2020221849-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2020-11-05 | — | — | WO | disclosed |
| EP-3703666-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | Universidade de Santiago de Compostela (ES) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | FAAH 2556/4885MGLL 2631/4885MEN1 2022/4885 |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | FAAH 2556/4885MGLL 2631/4885MEN1 2022/4885 |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | FAAH 4410/4885MGLL 4390/4885MEN1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.